Lv11
70 积分 2024-04-08 加入
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
2小时前
已完结
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
11天前
已完结
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
27天前
已完结
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer
1个月前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
1个月前
已完结
Induction Therapy for Non-Small Cell Lung Cancer
1个月前
已完结
Oligometastases: Emerging Evidence
3个月前
已完结
Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial
3个月前
已完结
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
3个月前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
3个月前
已完结
皖公网安备34019202002308
